SCHEMBL27338337

SCHEMBL27338337

NCc1cccc(Nc2cc(NCC(F)(F)F)ncn2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 5/20 0.46
THRB P10828 1/20 0.43
JAK3 P52333 3/20 0.42
SYK P43405 1/20 0.42
JAK2 O60674 2/20 0.41
ABL1 P00519 1/20 0.41
BCR P11274 1/20 0.41
TNNI3K Q59H18 2/20 0.39
CFD P00746 2/20 0.39
AURKA O14965 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
ERBB4 Q15303 1/20 0.38
CCNT1 O60563 1/20 0.38
MAP4K4 O95819 1/20 0.38
CDK1 P06493 1/20 0.38
CDK4 P11802 1/20 0.38
CCNB1 P14635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27318793 0.83 EGFR (0.67) EGFRJAK3JAK2TNNI3KCFD
SCHEMBL27332161 0.82 JAK3 (0.58) EGFRJAK3JAK2ABL1MEN1
SCHEMBL27345372 0.80 EGFR (0.46) EGFRJAK3TNNI3KCFDMEN1
SCHEMBL27338332 0.80 EGFR (0.49) EGFRJAK3JAK2TNNI3KCFD
SCHEMBL27401062 0.80 EGFR (0.49) EGFRJAK3JAK2TNNI3KCFD
SCHEMBL27339281 0.80 HTR7 (0.52) EGFRJAK3TNNI3KCFDMEN1
SCHEMBL27337227 0.80 JAK3 (0.50) EGFRJAK3JAK2TNNI3KCFD
SCHEMBL27323503 0.79 EGFR (0.45) EGFRTHRBTNNI3KCFDMEN1
SCHEMBL2063772 0.79 MEN1 (0.48) EGFRJAK3ABL1BCRTNNI3K
SCHEMBL27319709 0.79 EGFR (0.58) EGFRJAK3CFDMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1047778-C Pyrimido [5-4-d] pyrimidines, drugs containing these compounds, their use and process for preparing them THOMAE GMBH DR K (DE) 1999-12-29 CN disclosed